10-K: Arch Therapeutics Reports Fiscal Year 2023 Results, Faces Going Concern Uncertainty

Arch Therapeutics reports its fiscal year 2023 results, highlighting increased revenue but also significant losses and substantial doubt about its ability to continue as a going concern.

Summary

• Arch Therapeutics, a biotechnology company focused on its AC5 self-assembling technology, reported a net loss of $6.98 million for fiscal year 2023, compared to a $5.28 million loss in the previous year.
• The company's operating expenses remained high, with selling, general, and administrative costs at $4.37 million and research and development expenses at $670,880.
• Revenue increased to $75,724 in fiscal year 2023, up from $15,652 in the previous year, primarily from sales of its AC5 Advanced Wound System.
• The company's cash position decreased to $222,720 as of September 30, 2023, down from $746,940 the previous year.
• Arch Therapeutics acknowledges substantial doubt about its ability to continue as a going concern, with current cash expected to meet needs only into the second quarter of fiscal 2024.
• The company has funded operations primarily through debt and equity financings and expects to continue to rely on these sources.
• The company has a significant amount of debt, including convertible notes, which are secured by substantially all of its assets.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments in revenue and market access, but the significant losses, cash burn, and going concern uncertainty weigh heavily on the overall sentiment. The repeated delays in the Uplist Transaction and the need for further capital raises also contribute to a negative outlook.

Positives

• The company has seen a significant increase in revenue from the sale of its AC5 Advanced Wound System.
• The company has secured a dedicated HCPCS code for its AC5 Advanced Wound System, which should improve reimbursement.
• The company has expanded its reach into government channels through a partnership with Lovell Government Services.
• The company has completed two randomized controlled clinical studies to date.

Negatives

• The company experienced a net loss of $6.98 million for fiscal year 2023.
• The company's operating expenses remain high.
• The company's cash position has decreased significantly.
• The company has substantial doubt about its ability to continue as a going concern.
• The company has a significant amount of debt, including convertible notes, which are secured by substantially all of its assets.

Risks

• The company's ability to continue as a going concern is in doubt.
• The company may not be able to secure additional capital when needed.
• The company's obligations under the 2022 Notes are secured by substantially all of its assets.
• The company's business may be materially adversely affected by the coronavirus (COVID-19) pandemic.
• The company's flagship product is novel without any history of use in the clinical fields in which it is marketed.
• The company's additional product candidates are inherently risky because they are based on novel technologies.
• The company faces competition from companies that have greater resources.
• The company's Common Stock trades in the over-the-counter market in low volumes and at volatile prices.
• The company's Common Stock is a penny stock.

Future Outlook

The company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of current and potential products. The company anticipates that its operating and other expenses will continue to increase as it continues to implement its business plan and pursue and achieve its goals. The company believes that its current cash on hand will meet its anticipated cash requirements into the second quarter of fiscal 2024.

Management Comments

• The Company has recently devoted substantially all of its operational effort to the market adoption and commercial sales of AC5 Advanced Wound System, its first product.
• The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of current and potential products.
• There exists substantial doubt about the Companys ability to continue as a going concern for one year past the issuance of the financial statements.

Industry Context

The document highlights the competitive landscape in the wound care market, noting that while the market is large, it is also crowded and challenging. The company is developing technology for both Dermal Sciences and BioSurgery applications, seeking to provide a product set with broad utility in external and internal applications. The document also notes the increasing trend of minimally invasive surgeries and the need for better hemostatic and sealant products.

Comparison to Industry Standards

• The document notes that the advanced wound dressings market accounts for approximately $2 billion in annual revenues, while the overall wound care market is projected to surpass $10 billion in the United States.
• The document cites a 2015 MedMarket Diligence, LLC report, stating that the market for hemostatic agents and sealants achieved approximately $4.2 billion in worldwide sales in 2015 and was projected to reach $4.8 billion in 2017 and surpass $7.5 billion in 2022.
• The document notes that commercially available hemostatic agents can cost between $50 and $500 per procedure.
• The document cites a 2017 report by Chan et al indicating that the mean one-year cost of care from the perspective of a health-care public payer was $44,200 for a diabetic foot ulcer, $15,400 for a pressure ulcer and $11,000 for a leg ulcer.

Management Changes

Corporate Governance

Related Party Transactions

• On July 6, 2022 a Board member, Laurence Hicks, and executive officers, Terrence W. Norchi and Michael S. Abrams, invested in the 2022 Senior Secured Convertible Notes. The investment made in the 2022 Senior Secured Convertible Notes made by the Board member and executive officers totaled approximately $80,000.
• On August 10, 2023 a Board member, Laurence Hicks, and executive officers, Terrence W. Norchi and Michael S. Abrams, invested in the 2022 Senior Secured Convertible Notes. The investment made in the 2022 Senior Secured Convertible Notes made by the Board member and executive officers totaled approximately $7,500.

Stakeholder Impact

• Shareholders face significant risk of dilution from future capital raises.
• Shareholders face the risk of losing their investment due to the company's going concern uncertainty.
• Employees may face uncertainty due to the company's financial instability.
• Customers may be impacted by potential supply chain disruptions or changes in product availability.
• Creditors face the risk of non-payment due to the company's financial instability.

Next Steps

• The company plans to further develop its product clinical profile.
• The company plans to enhance product packaging features.
• The company plans to identify and address opportunities for supply chain efficiencies.
• The company plans to assess its technology platform to identify and select product candidates for potential advancement into development.
• The company plans to seek additional funding as required to support its operations.
• The company plans to continue to expand and enhance its financial and operational reporting and controls.
• The company plans to pursue commercial partnerships.
• The company plans to expand and enhance its intellectual property portfolio.

Key Dates

Keywords

AC5 Advanced Wound System, biotechnology, wound care, hemostasis, self-assembling peptide, medical device, convertible notes, clinical trials, regulatory approval, commercialization